Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jan 23:7:51-63.
doi: 10.2147/CMAR.S72814. eCollection 2015.

New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials

Svetlana Kotova  1 , Raymond M Wong  2 , Robert B Cameron  1
Affiliations
Review

New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials

Svetlana Kotova et al. Cancer Manag Res. .

Abstract

Malignant pleural mesothelioma (MPM) is a rare tumor that is challenging to control. Despite some benefit from using the multimodality-approach (surgery, combination chemotherapy and radiation), survival remains poor. However, current research produced a list of potential therapies. Here, we summarize significant new preclinical and early clinical developments in treatment of MPM, which include mesothelin specific antibody and toxin therapies, interleukin-4 (IL-4) receptor toxins, dendritic cell vaccines, immune checkpoint inhibitors, and gene-based therapies. In addition, several local modalities such as photodynamic therapy, postoperative lavage using betadine, and cryotherapy for local recurrence, have also shown to be effective for local control of disease.

Keywords: MPM; local therapies; new targeted; systemic.

PubMed Disclaimer

References

    1. Seer.cancer.gov [database on the Internet] Age adjusted incidence of mesothelioma all ages (SEER-13) Bethesda, MD: Surveillance, Epidemiology, and End Results Program; [Accessed July 5, 2014]. Available from: http://seer.cancer.gov/faststats/selections.php?#Output.
    1. Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011;89(10):716–724. 724A. - PMC - PubMed
    1. Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012;1(4):491–496. - PMC - PubMed
    1. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113(3):723–731. - PubMed
    1. Flores RM, Zakowsky M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol. 2007;2(10):957–965. - PubMed